Drug Developer Opts for RWE Model to Study Psychedelic Therapies
Albert Labs, a UK-based R&D company, is exploring a new way to fast track how quickly patients can access psychedelic therapies by leveraging Real World Evidence (“RWE”) while developing the medicines needed to manage a variety of mental health ailments.
While the current range of pharmaceutical medicines for mental health issues is diverse, an increasing number of patients aren’t responding to these conventional treatments. Additionally, some mental health issues seem to have no current treatment modality indicated for them. A case in point is cancer-induced anxiety, which can lower treatment compliance rates and even drive up the number of suicides in this patient population.
Albert Labs hopes to use RWE studies to expedite access to psilocybin, MDMA, psilocin and other psychedelic treatments to patients in the United Kingdom as well as mainland Europe, before going global.
Malcolm Barrat Johnson, the CMO at Albert Labs, explains that the approach the company is taking isn’t altogether new as it was the same method that was used to develop COVID-19 vaccines in a shorter time than many thought possible. Albert Labs is going to work with oncology units in several UK treatment centers in addition to collaborating with diverse teams of faculty at leading academic institutions in order to develop effective treatments for cancer-related depression, existential crisis and anxiety.
The company explains that it is aiming to address the unmet medical needs of approximately 3 million cancer patients in the UK and 5 million in the United States. as well as a possible 5 million in Europe generally.
Those patients are a vital group to focus on because the antidepressants normally prescribed for depression, anxiety and other cancer-related mental health concerns often interact adversely with the cancer treatments which the patients take. Additionally, patients have to take these drugs for years or even a lifetime while exposing themselves to those attendant issues of the medications.
This is where the psychedelic remedies that Albert Labs is developing come in. As a class of medicines, psychedelics have been found to work differently from existing treatments since substances such as psilocybin work to rewire how the brain works so that the patient breaks the patterns that have kept them stuck in a near-endless cycle of mental health issues.
RWE studies offer a more affordable way to develop effective medicines in a shorter time, which is why Albert Labs has opted to use this approach. The company intends to get UK regulatory approval for its planned study in the coming months, conduct the trials immediately afterwards and publish its findings early next year.
As RWE studies are explored as a way to supercharge the search for viable psychedelic treatments, companies such as Pure Extracts Technologies Corp. (CSE: PULL) (OTC: PRXTF) in the plant extraction space are also prepared to play their role in ensuring that the large-scale production of those active pharmaceutical ingredients is done cost efficiently.
NOTE TO INVESTORS: The latest news and updates relating to Pure Extracts Technologies Corp. (CSE: PULL) (OTC: PRXTF) are available in the company’s newsroom at https://ibn.fm/PULL
Please see full terms of use and disclaimers on the PsychedelicNewsWire website applicable to all content provided by PNW, wherever published or re-published: https://www.PsychedelicNewsWire.com/Disclaimer
Albert Labs, a UK-based R&D company, is exploring a new way to fast track how quickly patients can access psychedelic therapies by leveraging Real World Evidence (“RWE”) while developing the medicines needed to manage a variety of mental health ailments.
While the current range of pharmaceutical medicines for mental health issues is diverse, an increasing number of patients aren’t responding to these conventional treatments. Additionally, some mental health issues seem to have no current treatment modality indicated for them. A case in point is cancer-induced anxiety, which can lower treatment compliance rates and even drive up the number of suicides in this patient population.
Albert Labs hopes to use RWE studies to expedite access to psilocybin, MDMA, psilocin and other psychedelic treatments to patients in the United Kingdom as well as mainland Europe, before going global.
Malcolm Barrat Johnson, the CMO at Albert Labs, explains that the approach the company is taking isn’t altogether new as it was the same method that was used to develop COVID-19 vaccines in a shorter time than many thought possible. Albert Labs is going to work with oncology units in several UK treatment centers in addition to collaborating with diverse teams of faculty at leading academic institutions in order to develop effective treatments for cancer-related depression, existential crisis and anxiety.
The company explains that it is aiming to address the unmet medical needs of approximately 3 million cancer patients in the UK and 5 million in the United States. as well as a possible 5 million in Europe generally.
Those patients are a vital group to focus on because the antidepressants normally prescribed for depression, anxiety and other cancer-related mental health concerns often interact adversely with the cancer treatments which the patients take. Additionally, patients have to take these drugs for years or even a lifetime while exposing themselves to those attendant issues of the medications.
This is where the psychedelic remedies that Albert Labs is developing come in. As a class of medicines, psychedelics have been found to work differently from existing treatments since substances such as psilocybin work to rewire how the brain works so that the patient breaks the patterns that have kept them stuck in a near-endless cycle of mental health issues.
RWE studies offer a more affordable way to develop effective medicines in a shorter time, which is why Albert Labs has opted to use this approach. The company intends to get UK regulatory approval for its planned study in the coming months, conduct the trials immediately afterwards and publish its findings early next year.
As RWE studies are explored as a way to supercharge the search for viable psychedelic treatments, companies such as Pure Extracts Technologies Corp. (CSE: PULL) (OTC: PRXTF) in the plant extraction space are also prepared to play their role in ensuring that the large-scale production of those active pharmaceutical ingredients is done cost efficiently.
NOTE TO INVESTORS: The latest news and updates relating to Pure Extracts Technologies Corp. (CSE: PULL) (OTC: PRXTF) are available in the company’s newsroom at https://ibn.fm/PULL
Please see full terms of use and disclaimers on the PsychedelicNewsWire website applicable to all content provided by PNW, wherever published or re-published: https://www.PsychedelicNewsWire.com/Disclaimer
